We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

38 hedge funds and large institutions have $175M invested in Protagonist Therapeutics in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

47.74% more ownership

Funds ownership: 0% → 47.74% (+48%)

21% more capital invested

Capital invested by funds: $145M → $175M (+$30.2M)

12% more funds holding

Funds holding: 34 → 38 (+4)

Holders
38
Holders Change
+4
Holders Change %
+11.76%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
8
Increased
21
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.44M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.74M
3
Northern Trust
Northern Trust
Illinois
+$1.38M
4
BFA
BlackRock Fund Advisors
California
+$846K
5
State Street
State Street
Massachusetts
+$692K

Top Sellers

1
BI
BVF Inc
California
-$7.92M
2
CAM
Cormorant Asset Management
Massachusetts
-$1.78M
3
DCM
DAFNA Capital Management
California
-$1.74M
4
RCM
RA Capital Management
Massachusetts
-$1.38M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$55.1M +$8.44M +378,448 +18%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$33.7M -$1.11M -50,000 -3%
PI
3
Pharmstandard International
Luxembourg
$21.6M +$21.9M +983,570 New
CAM
4
Cormorant Asset Management
Massachusetts
$15.8M -$1.78M -80,000 -10%
RCM
5
RA Capital Management
Massachusetts
$14.6M -$1.38M -61,848 -8%
FCMI
6
Foresite Capital Management III
California
$7.62M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.82M +$3.74M +167,611 +118%
BFA
8
BlackRock Fund Advisors
California
$5.37M +$846K +37,931 +18%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$2.19M +$146K +6,548 +7%
State Street
10
State Street
Massachusetts
$2.03M +$692K +31,042 +51%
Northern Trust
11
Northern Trust
Illinois
$1.81M +$1.38M +62,043 +308%
BIT
12
BlackRock Institutional Trust
California
$1.6M +$150K +6,725 +10%
DCM
13
DAFNA Capital Management
California
$1M -$1.74M -78,218 -63%
GAMA
14
Graticule Asia Macro Advisors
New York
$700K – – –
SIM
15
Spark Investment Management
New York
$692K -$236K -10,600 -25%
BIM
16
BlackRock Investment Management
Delaware
$658K +$23K +1,032 +4%
TCIM
17
TIAA CREF Investment Management
New York
$504K +$286K +12,825 +127%
Morgan Stanley
18
Morgan Stanley
New York
$501K +$503K +22,578 +11,289%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$500K +$190K +8,513 +60%
California State Teachers Retirement System (CalSTRS)
20
California State Teachers Retirement System (CalSTRS)
California
$345K -$8.92K -400 -2%
Charles Schwab
21
Charles Schwab
California
$291K +$294K +13,200 New
JP Morgan Chase
22
JP Morgan Chase
New York
$233K +$190K +8,502 +403%
TA
23
Teachers Advisors
New York
$208K +$31.7K +1,424 +18%
Citigroup
24
Citigroup
New York
$168K +$157K +7,023 +1,131%
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$126K +$128K +5,746 New
1
2

PTGX Hedge Fund Activity: Q4 2016 in Review

38 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2016, worth a combined $175M — up 21% from $145M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new PTGX positions and 4 closed out — a net gain of 4 holders — while 21 added to existing stakes and 6 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $8.44M. The largest seller was BVF Inc, exiting entirely with an estimated $7.92M sold.

  • 38 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2016, up from 34 in Q3 2016.
  • Funds reported $175M of Protagonist Therapeutics stock for Q4 2016, up 21% quarter-over-quarter.
  • 8 funds opened new Protagonist Therapeutics positions in Q4 2016 and 4 closed out, a net change of +4 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2016 was Fidelity Investments, an estimated $8.44M added.
  • The largest Protagonist Therapeutics seller in Q4 2016 was BVF Inc, an estimated $7.92M sold.

Based on aggregated 13F filings for Q4 2016.